Aardvark Therapeutics Inc’s recent filing unveils that its Director VICKERS VENT GLB DEEP-TECH FND acquired Company’s shares for reported $93413.0 on Sep 15 ’25. In the deal valued at $9.02 per share,10,360 shares were bought.
Then, Lee Tien-Li bought 9,000 shares, generating $71,212 in total proceeds. Upon buying the shares at $7.91, the Chief Executive Officer now owns 1,522,384 shares.
Before that, Lee Tien-Li bought 6,000 shares. Aardvark Therapeutics Inc shares valued at $46,926 were divested by the Chief Executive Officer at a price of $7.82 per share. As a result of the transaction, Lee Tien-Li now holds 1,528,384 shares, worth roughly $15.21 million.
H.C. Wainwright initiated its Aardvark Therapeutics Inc [AARD] rating to a Buy in a research note published on June 30, 2025; the price target was $40. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in early March with a ‘”an Outperform”‘ rating. Morgan Stanley began covering AARD with “an Overweight” recommendation on March 10, 2025. Cantor Fitzgerald started covering the stock on March 10, 2025. It rated AARD as “an Overweight”.
Price Performance Review of AARD
On Monday, Aardvark Therapeutics Inc [NASDAQ:AARD] saw its stock jump 15.83% to $9.95. Over the last five days, the stock has gained 21.34%. Nevertheless, the stocks have fallen -30.47% over the past one year.
How much short interest is there in Aardvark Therapeutics Inc?
A steep rise in short interest was recorded in Aardvark Therapeutics Inc stocks on 2025-08-29, growing by 43099.0 shares to a total of 0.67 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 0.62 million shares. There was a rise of 6.47%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 10, 2025 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $22 price target.
